<DOC>
	<DOCNO>NCT02910102</DOCNO>
	<brief_summary>This study seek evaluate effect intepirdine ( RVT-101 ) gait balance patient Alzheimer 's Disease , Dementia Lewy Bodies Parkinson 's Disease Dementia .</brief_summary>
	<brief_title>Study Evaluating Intepirdine ( RVT-101 ) Gait Balance Subjects With Dementia</brief_title>
	<detailed_description>To assess effect intepirdine ( RVT-101 ) versus placebo quantitative qualitative gait balance parameter . Each subject randomize 1:1 one follow sequence : Sequence 1 : AB = RVT-101 35 mg early treatment period Placebo late treatment period Sequence 2 : BA = Placebo early treatment period RVT-101 35 mg late treatment period Treatment A = RVT-101 35 mg daily . Treatment B = Placebo daily .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>Key 1 . Male female subject clinical diagnosis Alzheimer 's disease ( AD ) , dementia Lewy body ( DLB ) , Parkinson 's disease dementia ( PDD ) . 2 . Mini Mental State Examination score 14 26 3 . Gait impairment , assess history gather clinical investigator quantitative measurement 4 . Subjects must stable background acetylcholinesterase inhibitor therapy Key 1 . History and/or evidence CNS disorder could interpret cause dementia ( opinion investigator ) 2 . Any clinically relevant concomitant disease , opinion investigator , make subject unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>RVT-101</keyword>
	<keyword>intepirdine</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Dementia Lewy body</keyword>
	<keyword>Lewy body dementia</keyword>
	<keyword>Parkinson 's Disease Dementia</keyword>
</DOC>